Crohn\'s disease (CD), a type of inflammatory bowel disease (IBD), is a disorder that causes inflammation and ulceration throughout the gastrointestinal tract, particularly in the small and large intestines, producing gastrointestinal symptoms such as diarrhea and abdominal pain, which lead to weight loss and nutritional impairment. Many years of research on the causes of CD have suggested that it arises from immunological abnormalities against a backdrop of both genetic and environmental factors;\[[@ref1][@ref2][@ref3][@ref4]\] however, its mechanism is yet to be elucidated in detail. Numerous studies have described the value of treating patients with CD with immunoregulatory therapy employing biological agents such as anti-tumor necrosis factor-α (TNF-α) agents or immunomodulators (IM);\[[@ref5]\] however, these immunoregulatory therapies may increase the risk of malignant neoplasm, severe opportunistic infection, bone marrow suppression, or hepatosplenic T-cell lymphoma.\[[@ref6][@ref7][@ref8][@ref9][@ref10]\] In addition, the existence of secondary nonresponders whose response to treatment becomes weaker the longer immunoregulatory therapy continues is becoming a clinical issue.\[[@ref11][@ref12]\] An elemental diet (ED) has been shown to be extremely safe for patients with CD, which improves their nutritional status, clinical symptoms, and morphological findings; in Japan, it is the first-line therapy for adults and pediatric patients.\[[@ref13][@ref14]\] Although the mechanism accounting for its therapeutic effects has not been clarified, recent studies have shown that ED modifies the composition of the intestinal microbiome, which plays a major causative role in CD.\[[@ref15][@ref16]\] Furthermore, certain amino acids have been shown to have major involvement in chronic inflammation, and elucidating the therapeutic efficacy of bowel rest and ED other than nutritional supplements is currently underway.\[[@ref17]\] Histidine (His) and tryptophan (Trp) in particular have been shown to be strongly correlated with the disease activity of IBD. Statistical analysis and conversion to indices of the balance of amino acid concentrations in blood by means of a multivariate index using AminoIndex technology (MIAI) has been found to be useful for diagnosing CD and assessing disease activity.\[[@ref18][@ref19][@ref20]\] Studies using drug-induced epithelial damage colitis models have also indicated that nutritional supplementation with ED and bowel rest and some amino acids, such as His, glutamine, and glycine, directly suppresses colitis.\[[@ref21][@ref22][@ref23][@ref24]\] Although attention is already focused on the association between the pathology of CD and amino acid metabolism, no study has investigated the relationship between disease activity associated with nutritional therapy and changes in plasma amino acid concentrations in patients with active CD. Therefore, the objective of the present study was to elucidate the association between changes in the concentration of amino acids, particularly essential amino acids (EAA) that cannot be synthesized in the human body, in the plasma of patients with CD due to ED and its therapeutic efficacy.

PATIENTS AND METHODS {#sec1-1}
====================

Patients {#sec2-1}
--------

The study included patients with active CD \[Crohn\'s disease activity index (CDAI) of ≥150\]\[[@ref25][@ref26]\] who were treated at the Dokkyo Medical University between October 2010 and December 2011. ED therapy with Elental^®^ (300 kcal/pack) was provided for 12 weeks. Patients who were not previously treated with ED were defined as the new ED group, and those who had previously undergone maintenance therapy with ED (≥900 kcal/day) were defined as the previous ED group. In the previous ED group, the amount of Elental^®^ was increased as far as the patients\' sensitivity permitted. No restrictions were placed on the use of anti-TNF-α therapy with adalimumab (ADA) or infliximab (IFX) during the treatment period. The CDAI, blood biochemistry test results, and plasma amino acid concentrations were measured before starting the treatment and after the treatment (12 weeks). The association between changes in the plasma amino acid concentrations before and after the treatment as well as the response to treatment were assessed. We used as standard the median plasma amino acid concentration in healthy controls (HCs) reported by Hisamitsu *et al*.\[[@ref20]\] Patients whose CDAI score was \<150 due to treatment were classed as having achieved remission, and those whose score did not reach this point were regarded as not having achieved remission.

Multivariate index using AminoIndex technology analysis {#sec2-2}
-------------------------------------------------------

MIAI (CDa/CDr), which is regarded to be valuable for distinguishing between remission and nonremission in CD, was calculated according to the following formula: MIAI (CDa/CDr) =16.474 -- 3.342 × \[His\] -- 5.190 × \[Trp\] + 1.857 × \[Tau\] +2.715 × \[methionine (Met)\].\[[@ref20]\] Plasma amino acid concentrations were measured using an SRL automated amino acid analysis liquid chromatography--mass spectrometry system (Shimadzu).

Statistical analysis {#sec2-3}
--------------------

Data were expressed as mean ± standard deviation, and plasma amino acid concentrations (nonparametric data) were expressed as medians (interquartile ranges). A *t*-test was used to compare parametric data between the two groups, and a paired *t*-test was used to determine differences in one-sample analyses. Wilcoxon\'s rank sum test was used to compare plasma amino acid concentrations between the two groups, and Wilcoxon\'s signed-rank test was used to determine differences in one-sample analyses. An χ^2^ test was used to investigate bias in the frequency of data on each scale between the two groups. Pearson\'s product-moment correlation coefficient was calculated to investigate the correlation between two stochastic variables. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic accuracy of the MIAI and CRP values, and the area under the ROC curve (ROC AUC) for clinical remission was calculated. A value of *P* \< 0.05 was considered significant. All statistical analyses were performed using JMP software, version 9.0.0 (SAS Institute Inc., Cary, NC, USA).

Ethical considerations {#sec2-4}
----------------------

The study protocol was approved by the institutional review board of Dokkyo Medical University, and all participants provided informed written consents. The performance of this study adhered to the principles of the Declaration of Helsinki for medical research involving human participants.

RESULTS {#sec1-2}
=======

Study participants {#sec2-5}
------------------

The participants were 25 patients with CD that was active during the study period. [Table 1](#T1){ref-type="table"} summarizes the patients\' background characteristics before the study started. No patient took systemic corticosteroids during the treatment period, however, 4 (16%) had been given thiopurine before treatment was started, and 1 received azathiopurine during the treatment period with the goal of maintaining remission. Ten patients (40%) were already undergoing maintenance therapy with anti-TNF-α agents (IFX or ADA) at the start of the treatment, and 9 (36%) with high disease activity were started on new anti-TNF-α therapy during the treatment period. There were no significant differences in the characteristics of patients in the new ED group (*n* = 11) and the previous ED group (*n* = 14), except for the amount of ED used.

###### 

Patients' characteristics before treatment

![](SJG-23-20-g001)

Changes after treatment {#sec2-6}
-----------------------

[Table 2](#T2){ref-type="table"} shows changes in the disease activity of all 25 patients after the treatment. There were significant decreases in both the CDAI (236.12 to 134.40, *P* \< 0.001) and CRP level (2.12 mg/dL to 1.02 mg/dL, *P* = 0.007), and 17 of 25 patients (68%) achieved remission (CDAI \<150). All physical findings and blood biochemistry test results, except the total protein level, improved in the 17 patients who achieved remission, and the concentrations of the plasma amino acids His, Trp, valine (Val), Met, and EAA increased \[[Table 3](#T3){ref-type="table"}\]. There was no change in any of the parameters, including the plasma amino acid concentrations, for the 8 patients who did not achieve remission.

###### 

Comparison of all patients in before and after treatment
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###### 

Comparison of all patients in the remission and non-remission groups before and after treatment
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To investigate the value of the MIAI (CDa/CDr) as a CD activity marker, as reported by Hisamatsu *et al*., we analyzed the correlations between the MIAI and CDAI, and between the MIAI and CRP in all 25 patients before and after treatment (*n* = 50). There were significant correlations between both the MIAI and CDAI (*r* = 0.475, *P* \< 0.001), and between the CRP and CDAI (*r* = 0.618, *P* \< 0.001). There was no significant correlation, however, between the level of CRP (the inflammatory marker) and MIAI (*r* = 0.271, *P* = 0.057) \[[Figure 1](#F1){ref-type="fig"}\]. The ROC AUC of the MIAI for diagnosing remission (CDAI: \<150) was 0.688, which was similarly high compared to that of the CRP level (ROC AUC = 0.699). The MIAI also decreased as disease activity improved with treatment \[[Figure 2](#F2){ref-type="fig"}\].

![(a) Analysis of the correlation between the Crohn\'s disease activity index (CDAI) and multivariate index using AminoIndex™ (MIAI) technology in 25 patients before and after treatment (*n* = 50). (b) Analysis of the correlation between the CDAI and C-reactive protein (CRP) level in 25 patients before and after treatment (*n* = 50). (c) Analysis of the correlation between the MIAI and CRP level in 25 patients before and after treatment (*n* = 50)](SJG-23-20-g004){#F1}

![Comparison of the multivariate index using AminoIndex™technology and Crohn\'s disease activity index in the remission and nonremission groups before and after treatment](SJG-23-20-g005){#F2}

New ED group vs. previous ED group {#sec2-7}
----------------------------------

[Table 4](#T4){ref-type="table"} shows comparisons of patients in the new ED group (*n* = 11) and the previous ED group (*n* = 14) before and after treatment. In the new ED group, the amount of ED increased significantly from 0 packs/day to 4.83 packs/day (*P* \< 0.001), whereas in the previous ED group, it increased from 4.07 packs/day to 5.07 packs/day, which was a high level; the difference was still significant (*P* = 0.005) but much smaller than that for the new ED group. Anti-TNF-α therapy was started by 4 patients in the new ED group and 5 in the previous ED group, with no significant difference between both the groups. In terms of the response to treatment of patients in the two groups, 10 (90.9%) patients in the new ED group and 7 (50%) in the previous ED group achieved remission, all of whom exhibited significant decreases in the CDAI and CRP level. Patients in the new ED group also exhibited increase in the nutritional indices, albumin, and body mass index after treatment, as well as increased levels of the plasma amino acids His, Trp, Val, and phenylalanine; however, none of these changes was observed in patients in the previous ED group.

###### 

Comparison of patients in the new elemental diet (ED) group and the previous ED group before and after treatment
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We then analyzed the correlation between the magnitude of changes in the CDAI and the magnitude of changes in plasma amino acid concentrations, and found that the magnitude of changes in the levels of plasma amino acids Trp, leucine, Val, Met, isoleucine, and EAA were also correlated with the magnitude of changes in the CDAI in the new ED group; however, no such correlation was evident in the previous ED group \[[Table 5](#T5){ref-type="table"}\].

###### 

Analysis of the correlation between the magnitude of changes in Crohn\'s disease activity index and the magnitude of changes in plasma amino acid concentrations in the new elemental diet (ED) group and the previous ED group
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DISCUSSION {#sec1-3}
==========

In our investigation of changes in the concentrations of plasma amino acids in patients with CD who underwent remission induction therapy with ED, we found that their concentrations varied in accordance with changes in the activity of CD. The MIAI also decreased as disease activity improved. These results reproduced the correlation between the MIAI and CDAI reported by Hisamatsu *et al*., and suggested that the MIAI may be a noninvasive objective biomarker for assessing disease activity and the response to treatment in patients with CD. In general, CDAI is widely used for evaluating disease activity of CD, however, it has a disadvantage in that its assessment incorporates subjectivity on the parts of both the doctor and patient.\[[@ref26]\] It is also known that CDAI does not always correlate with CRP and other inflammatory markers. On the other hand, there are studies showing CDAI to be a marker of disease activity in CD and to correlate with both CRP and fecal calprotectin. Therefore, the correlation between CDAI and CRP remains controversial.\[[@ref27]\] In our study, the two showed a correlation; this might be because we minimized interevaluator variability by providing education to our CDAI measurers and ensuring consensus among them; we also instructed the patients fill out the CDAI calculation sheet prospectively for 7 days prior to the medical consultation, consequently achieving accurate evaluations of disease activities in these patients. Both serum CRP and fecal calprotectin have been reported to be useful biomarkers for CD.\[[@ref27][@ref28][@ref29][@ref30]\] Specific breakdowns in the balance of plasma amino acid concentrations, which are regulated at a constant level by homeostasis maintenance functions, have been found to occur in diseases such as malignant tumors,\[[@ref31][@ref32][@ref33][@ref34][@ref35][@ref36]\] suggesting that the MIAI calculated to evaluate the activity of CD may constitute a disease-specific assessment. The MIAI is also a marker calculated from the viewpoint of nutritional status in terms of amino acid balance, and its combination with the CRP level and fecal calcitonin, which are mainly associated with inflammation, may enable the disease activity of CD to be evaluated from multiple perspectives.

A comparison of amino acid concentrations in patients who achieved remission (*n* = 17) and those who did not achieve remission (*n* = 8) showed particularly large increases in the concentrations of His, Trp, and other plasma amino acids in the remission group, whereas in the nonremission group there was no increase in the level of any EAA. As EAAs cannot be synthesized in the human body, they must be ingested as part of the diet, and unless all of them are eaten in the right quantities, with no excess or deficiency, they cannot be used effectively in the synthesis of proteins needed by the body.\[[@ref37][@ref38][@ref39][@ref40]\] This may imply that ED is important in terms of improving the amino acid balance.

A comparison of patients in the new and previous ED groups showed that although a poor nutritional status and EAA balance improved in the new ED group, no such improvement was seen in the previous ED group. An analysis of the correlation between the magnitude of changes in the CDAI and the magnitude of changes in plasma amino acid concentrations also found that these were only correlated in patients in the new ED group. These results suggested that the therapeutic efficacy of ED for CD may lie in improving poor nutrition and amino acid balance, and ED may be particularly effective for poorly nourished patients with CD who have not previously undergone this treatment. For patients such as those in the previous ED group whose caloric intake will probably not be further increased by ED, it may be necessary to consider immunoregulatory therapy with biologics or IM rather than increasing the amount of ED. The advent of biological agents in recent years has contributed to improving therapeutic outcomes for CD, however, the existence of secondary nonresponders whose response to treatment becomes weaker as it continues is becoming a clinical issue.\[[@ref11]\] In Europe and North America, attempts are being made to prevent the appearance of secondary nonresponders to IFX by using immunomodulators such as azathiopurine in combination with IFX from the start of therapy. A combination of these two types of drug has been reported to significantly extend the duration for which remission is maintained.\[[@ref12]\] However, because this may increase the risk of opportunistic infections and the development of hepatosplenic lymphoma, caution is required.\[[@ref6][@ref10]\] ED is an extremely safe therapy, and recent studies have found that the combination of nutritional therapy with IFX maintenance therapy significantly extends the duration of remission, suggesting that ED is a promising therapy when used during the administration of IFX.\[[@ref41][@ref42][@ref43]\] In the present study, we assessed whether remission had been achieved after 3 months of therapy, however, the efficacy of ED in improving plasma amino acid concentrations and CD activity suggested that it may also be an effective method of treatment for patients being treated with biologics. However, our results from this study are limited in that this was a small, nonrandomized cohort study; the gastrointestinal mucosa of CD patients was not analyzed; there may be potential bias in the selection of patients; and the treatment method cannot be ruled out. Further multicenter, large-scale randomized controlled trials are required in the future.

CONCLUSIONS {#sec1-4}
===========

Remission induction therapy with ED resulted in improved CDAI and increases in plasma amino acid concentrations, suggesting that plasma amino acid concentrations may provide a useful noninvasive marker for assessing disease activity in patients with CD and determining their response to treatment. No previous study has observed improvements in amino acid concentrations that parallel the condition of patients with CD after remission induction therapy with ED; thus, ED may be particularly effective for poorly nourished patients with CD who have not previously undergone this treatment.
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